Treatment of B-cell lymphoma with chimeric igg and single-chain Fv antibody-interleukin-2 fusion proteins

Blood

Volumn 92, Issue 6, 1998, Pages 2103-2112

  Liu, Shih Jen ^b   Sher, Yuh Pyng ^b   Ting, Chou Chik ^b   Liao, Kuang Wen ^b   Yu, Cheng Ping ^a   Tao, Mi Hua ^a  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 2; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ANTIGEN RECOGNITION; ARTICLE; B CELL LYMPHOMA; CHIMERA; FEMALE; GENETIC ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; TUMOR GROWTH;

EID: 0032531080     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.6.2103     Document Type: Article

References (58)

1. George AJ, Spooner RA, Epenetos AA: Applications of monoclonal antibodies in clinical oncology. Immunol Today 15:559, 1994
2. Hank JA, Robinson RR, Surfus J, Mueller BM, Reisfeld RA, Cheung NK, Sondel PM: Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res 50:5234, 1990
3. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA: Lymphokineactivated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823, 1982
4. Damle NK, Doyle LV, Bradley EC: Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors. J Immunol 137:2814, 1986
5. Chang AE. Rosenberg SA: Overview of interIeukin-2 as an immunotherapeutic agent. Semin Surg Oncol 5:385, 1989
6. Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL: Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 161:1169, 1985
7. Mule JJ, Shu S, Schwarz SL, Rosenberg SA: Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225:1487, 1984.
8. Ettinghausen SE, Rosenberg SA: Immunotherapy of murine sarcomas using lymphokine activated killer cells: Optimization of the schedule and route of administration of recombinant interleukin-2. Cancer Res 46:2784, 1986
9. Maas RA, Dullens HF, Den Otter W: Interleukin-2 in cancer treatment: Disappointing or (still) promising? A review. Cancer Immunol Immunother 36:141, 1993
10. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP, White DE: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319:1676, 1988
11. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485, 1985
12. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889, 1987
13. Forni G, Giovarelli M, Santoni A, Modesti A, Forni M: Interleukin 2 activated tumor inhibition in vivo depends on the systemic involvement of host immunoreactivity. J Immunol 138:4033, 1987
14. Fujiwara T, Sakagami K, Orita K: Antitumor effects of a new interleukin-2 slow delivery system on methylcholanthrene-induced fibrosarcoma in mice. J Cancer Res Clin Oncol 116:141, 1990
15. Pardoll DM: Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 13:399, 1995
16. Dranoff G, Mulligan RC: Gene transfer as cancer therapy. Adv Immunol 58:417, 1995
17. Zatloukal K, Schneeberger A, Berger M, Schmidt W, Koszik F, Kutil R, Gotten M, Wagner E, Buschle M, Maass G, Payer E, Stingl G, Birnstiel ML: Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters. J Immunol 154:3406, 1995
18. Maass G, Schmidt W, Berger M, Schilcher F, Koszik F, Schneeberger A, Stingl G, Birnstiel ML, Schweighoffer T: Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: Three consecutive stages may be required for successful tumor vaccination. Proc Natl Acad Sci USA 92:5540, 1995
19. Gillies SD, Young D, Lo KM, Foley RF, Reisfeld RA: Expression of genetically engineered immunoconjugates of lymphotoxin and a chimeric anti-ganglioside GD2 antibody. Hybridoma 10:347, 1991
20. Gillies SD, Reilly EB, Lo KM, Reisfeld RA: Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci USA 89:1428, 1992
21. Gillies SD, Young D, Lo KM, Roberts S: Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. Bioconjug Chem 4:230, 1993
22. Perek Y, Hurwitz E, Burowski D, Haimovich J: Immunotherapy of a murine B cell tumor with antibodies and F(ab')2 fragments against idiotypic determinants of its cell surface IgM. J Immunol 131:1600, 1983
23. Kaminski MS, Kitamura K, Maloney DG, Campbell MJ, Levy R: Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants. J Immunol 136:1123, 1986
24. Miller RA, Maloney DG, Warnke R, Levy R: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 306:517, 1982
25. Meeker TC, Lowder J, Maloney DG, Miller RA, Thielemans K, Warnke R, Levy R: A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 65:1349, 1985
26. Berinstein N, Levy R: Treatment of a murine B cell lymphoma with monoclonal antibodies and IL 2. J Immunol 139:971, 1987
27. Bergman Y, Haimovich J: Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H/eB origin. Eur J Immunol 7:413, 1977
28. Starnes CO, Carroll WL, Campbell MJ, Houston LL, Apell G, Levy R: Heterogeneity of a murine B cell lymphoma. Isolation and characterization of idiotypic variants. J Immunol 141:333, 1988
29. Maloney DG, Kaminski MS, Burowski D, Haimovich J, Levy R: Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: Characterization and use as probes for the biology of the tumor in vivo and in vitro. Hybridoma 4:191, 1985
30. Chen TT, Tao MH, Levy R: Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocytemacrophage colony-stimulating factor. J Immunol 153:4775, 1994
31. Tao MH, Levy R: Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362:755, 1993
32. Nickerson KG, Tao MH, Chen HT, Larrick J, Kabat EA: Human and mouse monoclonal antibodies to blood group A substance, which are nearly identical immunochemically, use radically different primary sequences. J Biol Chem 270:12457, 1995
33. Davis GT, Bedzyk WD, Voss EW, Jacobs TW: Single chain antibody (SCA) encoding genes: One-step construction and expression in eukaryotic cells. Biotechnology NY 9:165, 1991
34. Pantoliano MW, Bird RE, Johnson S, Asel ED, Dodd SW, Wood JF, Hardman KD: Conformational stability, folding, and ligand-binding affinity of single-chain Fv immunoglobulin fragments expressed in Escherichia coli. Biochemistry 30:10117, 1991
35. Campbell MJ, Carroll W, Kon S, Thielemans K, Rothbard JB, Levy S, Levy R: Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J Immunol 139:2825, 1987
36. Schick MR, Nguyen VQ, Levy S: Anti-TAPA-1 antibodies induce protein tyrosine phosphorylation that is prevented by increasing intracellular thiol levels. J Immunol 151:1918, 1993
37. Morelock MM, Rothlein R, Bright SM, Robinson MK, Graham ET, Sabo JR Owens R, King DJ, Norris SH, Scher DS, Wright JL, Adair JR: Isotype choice for chimeric antibodies affects binding properties. J Biol Chem 269:13048, 1994
38. Ting CC, Bushar GS, Rodrigues D, Herberman RB: Cell-mediated immunity to Friend virus-induced leukemia. I. Modification of 125IUdR release cytotoxicity assay for use with suspension target cells. J Immunol 115:1351, 1975
39. Mitenko PA, Ogivie RI: Pharmacokinetics of intravenous theophylline. Clin Pharmacol Ther 14:509, 1973
40. Hann HW, Stahlhut MW, Rubin R, Maddrey WC: Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice. Cancer 70:2051, 1992
41. Brugemann M, Williams GT, Bindon CI, Clark MR, Walker MR, Jefferis R, Waldmann H, Neuberger MS: Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 166:1351, 1987
42. Steplewski Z, Sun LK, Shearman CW, Ghrayeb J, Daddona P, Koprowski H: Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc Natl Acad Sci USA 85:4852, 1988
43. van der Schelling GP, Ijzermans JN, Kok TC, Scheringa M, Marquet RL, Splinter TA, Jeekel J: A phase I study of local treatment of liver metastases with recombinant tumour necrosis factor. Eur J Cancer 28a:1073, 1992
44. Sun WH, Burkholder JK, Sun J, Culp J, Turner J, Lu XG, Pugh TD, Ershler WB, Yang NS: In vivo cytokine gene transfer by gene gun reduces tumor growth in mice. Proc Natl Acad Sci USA 92:2889, 1995
45. Yokota T, Milenic DE, Whitlow M, Schlom J: Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52:3402, 1992
46. Colcher D, Bird R, Roselli M, Hardman KD, Johnson S, Pope S, Dodd SW, Pantoliano MW, Milenic DE, Schlom J: In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst 82:1191, 1990
47. Savage P, So A, Spooner RA, Epenetos AA: A recombinant single chain antibody interleukin-2 fusion protein. Br J Cancer 67:304, 1993
48. Bei R, Schlom J, Kashmiri SV: Baculovirus expression of a functional single-chain immunoglobulin and its IL-2 fusion protein. J Immunol Methods 186:245, 1995
49. Caligiuri MA, Zmuidzinas A, Manley TJ, Levine H, Smith KA, Ritz J: Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med 171:1509, 1990
50. Ravetch JV, Kinet JP: Fc receptors. Annu Rev Immunol 9:457, 1991
51. Fell HP, Gayle MA, Grosmaire L, Ledbetter JA: Genetic construction and characterization of a fusion protein consisting of a chimeric F(ab') with specificity for carcinomas and human IL-2. J Immunol 146:2446, 1991
52. Sabzevari H, Gillies SD, Mueller BM, Pancook JD, Reisfeld RA: A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc Natl Acad Sci USA 91:9626, 1994
53. Becker JC, Pancook JD, Gillies SD, Mendelsohn J, Reisfeld RA: Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc Natl Acad Sci USA 93:2702, 1996
54. Becker JC. Varki N, Gillies SD, Furukawa K, Reisfeld RA: Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J Clin Invest 98:2801, 1996
55. Becker JC, Pancook JD, Gillies SD, Furukawa K, Reisfeld RA: T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med 183:2361, 1996
56. Hu P, Hornick JL, Glasky MS, Yun A, Milkie MN, Khawli LA, Anderson PM, Epstein AL: C chimeric Lym-1/interleukin 2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake. Cancer Res 56:4998, 1996
57. Hornick JL, Khawli LA, Hu P, Lynch M, Anderson PM, Epstein AL: Chimeric CLL-1 antibody fusion proteins containing granulocytemacrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties. Blood 89:4437, 1997
58. Reisfeld RA, Gillies SD, Mendelsohn J, Varki NM, Becker JC: Involvement of B lymphocytes in the growth inhibition of human pulmonary melanoma metastases in athymic nu/nu mice by an antibody-lymphotoxin fusion protein. Cancer Res 56:1707, 1996